resistance mechanisms to flt3 inhibitors in aml
Published 6 years ago • 129 plays • Length 3:14Download video MP4
Download video MP3
Similar videos
-
1:24
mechanisms of resistance to flt3 inhibitors in aml and strategies to overcome this
-
2:59
using a genome-wide crispr screen to evaluate mechanisms of resistance to flt3 inhibitors in aml
-
1:50
mechanisms of gilteritinib resistance in flt3-mutated aml
-
4:47
the use of flt3 inhibitors in aml
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
7:46
updates in aml treatment and research from asco 2023
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
6:39
treatment failure and relapse in acute myeloid leukemia (aml)
-
1:49
the prognostic value of flt3-itd residual disease in aml
-
1:59
optimizing the use of flt3 inhibitors in aml: sequencing, post-transplant maintenance & more
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
2:08
comparing midostaurin to next-generation flt3 inhibitors in the frontline treatment of flt3-itd aml
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
2:40
an overview of the safety profile of flt3 inhibitors in aml
-
3:28
bax-mediated bh3 mimetic resistance in aml
-
2:29
combining menin/flt3/bcl2 inhibition as a treatment approach in flt3/npm1 double mutated aml
-
1:03
targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
-
1:26
combining flt3 and syk inhibition for aml
-
0:35
management & outcome of patients with cbf aml and flt3-itd
-
1:32
integrating midostaurin into flt3 positive aml treatment
-
1:28
assaying flt3 variant allele frequency in aml to determine response to treatment
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml